97-2819. Oral Dosage Form New Animal Drugs; Tetracycline Hydrochloride Soluble Powder  

  • [Federal Register Volume 62, Number 24 (Wednesday, February 5, 1997)]
    [Rules and Regulations]
    [Pages 5318-5319]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 97-2819]
    
    
    =======================================================================
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    
    21 CFR Part 520
    
    
    Oral Dosage Form New Animal Drugs; Tetracycline Hydrochloride 
    Soluble Powder
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Final rule.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
    drug regulations to reflect approval of an abbreviated new animal drug 
    application (ANADA) filed by Phoenix Scientific, Inc. The ANADA 
    provides for oral use of tetracycline hydrochloride soluble powder in 
    the drinking water of calves and swine for control and treatment of 
    certain diseases caused by pathogens susceptible to tetracycline, and 
    of chickens and turkeys for control of certain diseases caused by 
    pathogens susceptible to tetracycline.
    
    EFFECTIVE DATE: February 5, 1997.
    FOR FURTHER INFORMATION CONTACT: Melanie R. Berson, Center For 
    Veterinary Medicine (HFV-135), Food and Drug Administration, 7500 
    Standish Pl., Rockville, MD 20855, 301-594-1643.
    
    SUPPLEMENTARY INFORMATION: Phoenix Scientific, Inc., 3915 South 48th 
    Street Ter., P.O. Box 6457, St. Joseph, MO 64506-0457, filed ANADA 200-
    136, which provides for oral use of tetracycline hydrochloride soluble 
    powder in the drinking water of calves and swine for control and 
    treatment of certain conditions, and of chickens and turkeys for the 
    control of certain conditions, as follows: (1) For calves for control 
    and treatment of bacterial enteritis (scours) caused by Escherichia 
    coli, and bacterial pneumonia (shipping fever complex) associated with 
    Pasteurella spp., Actinobacillus pleuropneumoniae (Hemophilus spp.), 
    and Klebsiella spp. susceptible to tetracycline; (2) for swine for 
    control and treatment of bacterial enteritis (scours) caused by E. 
    coli, and bacterial pneumonia associated with Pasteurella spp., A. 
    pleuropneumoniae (Hemophilus spp.), and Klebsiella spp. susceptible to 
    tetracycline; (3) for chickens for control of chronic respiratory 
    disease (CRD or air-sac disease) caused by Mycoplasma gallisepticum and 
    E. coli; infectious synovitis caused by M. synoviae susceptible to 
    tetracycline; (4) for turkeys for control of infectious synovitis 
    caused by M. synoviae and bluecomb (transmissible enteritis or 
    coronaviral enteritis) complicated by bacterial organisms susceptible 
    to tetracycline.
        Approval of Phoenix's ANADA 200-136 tetracycline hydrochloride 
    soluble powder is as a generic copy of Fermenta's NADA 65-496 
    tetracycline hydrochloride soluble powder. ANADA 200-136 is approved as 
    of December 17, 1996, and the regulations are amended in 
    Sec. 520.2345d(a)(1) (21 CFR 520.2345d(a)(1)) to reflect the approval. 
    The basis of approval is discussed in the freedom of information 
    summary.
        In addition, due to enactment of the Generic Animal Drug and Patent 
    Term Restoration Act of 1988, the paragraph concerning NAS/NRC status 
    is outdated. Section 520.2345d is amended to remove paragraph (c).
        In accordance with the freedom of information provisions of 21 CFR 
    part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and 
    effectiveness data and information submitted to support approval of 
    this application may be seen in the Dockets Management Branch (HFA-
    305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, 
    Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.
        The agency has determined under 21 CFR 25.24 (d)(1)(i) that this 
    action is of a type that does not individually or cumulatively have a 
    significant effect on the human environment. Therefore, neither an 
    environmental assessment nor an environmental impact statement is 
    required.
    
    List of Subjects
    
    21 CFR Part 520
    
        Animal drugs.
        Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
    authority delegated to the Commissioner of Food and Drugs and 
    redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is 
    amended as follows:
    
    [[Page 5319]]
    
    PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS
    
        1. The authority citation for 21 CFR part 520 continues to read as 
    follows:
    
        Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act 
    (21 U.S.C. 360b).
    
    
    Sec.  520.2345d   [Amended]
    
        2. Section 520.2345d Tetracycline hydrochloride soluble powder is 
    amended in paragraph (a)(1) by removing ``047864, 054273, and 057561'' 
    and adding in its place ``047864, 054273, 057561, and 059130'' and by 
    removing and reserving paragraph (c).
    
        Dated: January 28, 1997.
    Michael J. Blackwell,
    Deputy Director, Center for Veterinary Medicine.
    [FR Doc. 97-2819 Filed 2-4-97; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Effective Date:
2/5/1997
Published:
02/05/1997
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final rule.
Document Number:
97-2819
Dates:
February 5, 1997.
Pages:
5318-5319 (2 pages)
PDF File:
97-2819.pdf
CFR: (2)
21 CFR 520.2345d(a)(1)
21 CFR 520.2345d